ArticlePhysiological research2025
Serum Glutathione and Malondialdehyde Levels as Predictors of Early Neurological Deficits and Short-Term Outcomes in Acute Cerebral Infarction.
Article in Physiological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Redox Imbalance and Antioxidant Adaptation in Acute Ischemic Stroke: Temporal Changes in Enzymatic and Non-Enzymatic Markers.Molecules (Basel, Switzerland) · 2026Article
- From Electron Imbalance to Network Collapse: Decoding the Redox Code of Ischemic Stroke for Biomarker-Guided Precision Neuroprotection.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the association between serum glutathione (GSH) and malondialdehyde (MDA) levels and early neurological deficits and short-term outcomes in individuals with acute cerebral infarction (ACI). The study included 114 patients with ACI within 48 hours of symptom onset, between January and August 2023, alongside 96 healthy individuals as a control group. Neurological deficits were assessed using the National Institute of Health Stroke Scale (NIHSS), classifying deficits as mild (<5) or moderate to severe (>/=5). Associations between GSH and MDA levels with early neurological deficits were analyzed. Short-term prognosis, assessed three months post-discharge using the Modified Rankin Scale (mRS), was examined in relation to GSH and MDA levels in patients with ACI. Independent predictors of neurological deficits and short-term outcomes were identified through binary logistic regression analysis. Compared to the control group, patients with ACI had higher rates of hypertension, diabetes, smoking, and alcohol consumption. Additionally, elevated levels of MDA, glycated hemoglobin, triglycerides, C-reactive protein (CRP), and D-dimer levels were observed, whereas GSH and high-density lipoprotein (HDL) levels were lower. Among those with moderate to severe ACI, levels of CRP, MDA, triglycerides, low-density lipoprotein (LDL), uric acid, and D-dimer levels were higher compared to mild ACI, while HDL and GSH levels were significantly lower. Low serum GSH levels and elevated MDA levels are associated with early neurological deficits and short-term prognosis in ACI, serving as independent risk factors for adverse prognosis. The combined assessment of MDA, infarct volume, and LDL provides enhanced predictive value for adverse prognosis in patients with ACI. Keywords: Acute cerebral infarction, Malondialdehyde, Neurological deficits, Serum glutathione, Short-term prognosis.
Indexed as
Identifiers
40432446PMC12148082What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.